← All organizations

Meda Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: MEDA Pharma GmbH & Co. KG | Meda Pharma GmbH & Co. KG (A Mylan Company) | MEDA PHARMS

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

Last known activity

Oct 30, 2023

Acquired by Mylan on Feb 10, 2016

Timeline

1970s

Apr 10, 1978
butabarbital— Marketing Organization
Nov 9, 1979
potassium iodide— NDA Organization

1990s

Jun 1, 1995
Meda Pharmaceuticals— Founded

2000s

Jun 10, 2005
metoclopramide— NDA Secondary Org
Aug 8, 2005
Viatris— Acquired

2010s

Aug 30, 2013
Acton Pharmaceuticals— Acquired
Jul 31, 2014
Rottapharm— Acquired
Feb 10, 2016
Mylan— Acquired By

Drugs by trial phase (40 distinct, 50 trials)

Phase 4 (1 own, 4 via acquisition)

Phase 3 (2 own, 21 via acquisition)

Phase 2 (2 own, 6 via acquisition)

Phase 1 (0 own, 4 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (9)

Subsidiaries (3 direct, 5 total across the full acquisition tree)

Recent trials (5)

NCT06126952Lead sponsorPhase 2Oct 30, 2023
NCT05637515CollaboratorPhase 3Nov 21, 2022
NCT04652245Lead sponsorPhase 4Dec 14, 2020
NCT03599791Lead sponsorPhase 3Jun 29, 2018
NCT03599791Study directorPhase 3Jun 29, 2018

Details

Founded: Solna, SE Jun 1, 1995
Last known activity: Oct 30, 2023